Real‐world treatment outcomes of immune checkpoint inhibitors used off‐label in oncology: A comprehensive cancer institution experience
Abstract Off‐label use (OLU) is quite common in oncology due to the complexity of cancer and the time‐consuming regulatory process. However, outcomes of OLU in cancer treatment remain unclear. This study aimed to evaluate the overall survival (OS), event‐free survival (EFS), duration of treatment (D...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Libro |
| Publicado: |
Wiley,
2024-02-01T00:00:00Z.
|
| Materias: | |
| Acceso en línea: | Connect to this object online. |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|